Aytu BioPharma, Inc.

DB:AY20 Stock Report

Market Cap: €7.7m

Aytu BioPharma Management

Management criteria checks 2/4

Aytu BioPharma's CEO is Josh Disbrow, appointed in Apr 2015, has a tenure of 7.25 years. total yearly compensation is $567.31K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth €123.42K. The average tenure of the management team and the board of directors is 0.4 years and 6.9 years respectively.

Key information

Josh Disbrow

Chief executive officer

US$567.3k

Total compensation

CEO salary percentage100.0%
CEO tenure8yrs
CEO ownership1.6%
Management average tenureless than a year
Board average tenure6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Josh Disbrow's remuneration changed compared to Aytu BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$78m

Sep 30 2022n/an/a

-US$83m

Jun 30 2022US$567kUS$567k

-US$110m

Mar 31 2022n/an/a

-US$111m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018US$606kUS$303k

-US$10m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017n/an/a

-US$20m

Sep 30 2017n/an/a

-US$21m

Jun 30 2017US$1mUS$250k

-US$23m

Mar 31 2017n/an/a

-US$31m

Dec 31 2016n/an/a

-US$33m

Sep 30 2016n/an/a

-US$32m

Jun 30 2016US$1mUS$250k

-US$28m

Compensation vs Market: Josh's total compensation ($USD567.31K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.

CEO

Josh Disbrow (47 yo)

8yrs

Tenure

US$567,308

Compensation

Mr. Joshua R. Disbrow, also known as Josh, is Chairman of the Board at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 and serves as its Chief Executive Officer. He serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Joshua Disbrow
Chairman & CEO8yrsUS$567.31k1.61%
€ 123.4k
Mark Oki
CFO, Secretary & Treasurer1.3yrsUS$352.60k0.27%
€ 20.4k
Christopher Brooke
Chief Operating Officerless than a yearno data1.63%
€ 125.1k
Victoria Cordova
Vice President of People & Cultureless than a yearno datano data
Jarrett Disbrow
Chief Business Officer & President of Consumer Healthless than a yearUS$793.41k0.36%
€ 27.4k
Greg Pyszczymuka
Chief Commercial Officerno datano data0.25%
€ 19.5k
Russ McMahen
Senior Vice President of Research & Developmentno datano datano data
Ryan Selhorn
Executive VP of Finance & Business Optimizationless than a yearno datano data

0.4yrs

Average Tenure

47yo

Average Age

Experienced Management: AY20's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Joshua Disbrow
Chairman & CEO7.3yrsUS$567.31k1.61%
€ 123.4k
Vivian Liu
Independent Directorless than a yearno data0.19%
€ 14.6k
John Donofrio
Lead Independent Director6.8yrsUS$75.00k0.021%
€ 1.6k
Carl Dockery
Independent Director7yrsUS$70.00k0.21%
€ 15.9k

6.9yrs

Average Tenure

57yo

Average Age

Experienced Board: AY20's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/08 13:46
End of Day Share Price 2023/01/10 00:00
Earnings2022/12/31
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aytu BioPharma, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jennifer KimCantor Fitzgerald & Co.
Jeffrey CohenLadenburg Thalmann & Company
Nazibur RahmanMaxim Group